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BACKGROUND: The objective of this study was to investigate the relationship between different target levels of glucose and the 
clinical outcomes of patients undergoing cardiac surgery with cardiopulmonary bypass.
METHODS: We designed a prospective study in a university hospital where 109 consecutive patients were enrolled during a 
six-month period. All patients were scheduled for open-heart surgery requiring cardiopulmonary bypass. Patients were randomly 
allocated into two groups. One group consisted of 55 patients and had a target glucose level of 80-130 mg/dl, while the other con-
tained 54 patients and had a target glucose level of 160-200 mg/dl. These parameters were controlled during surgery and for 36 
hours after surgery in the intensive care unit. Primary outcomes were clinical outcomes, including time of mechanical ventilation, 
length of stay in the intensive care unit, infection, hypoglycemia, renal or neurological dysfunction, blood transfusion and length 
of stay in the hospital. The secondary outcome was a combined end-point (mortality at 30 days, infection or length of stay in the 
intensive care unit of more than 3 days). A p-value of <0.05 was considered significant.
RESULTS: The anthropometric and clinical characteristics of the patients from each group were similar, except for weight and 
body mass index. The mean glucose level during the protocol period was 126.69 mg/dl in the treated group and 168.21 mg/dl in 
the control group (p<0.0016). There were no differences between groups regarding clinical outcomes, including the duration of 
mechanical ventilation, length of stay in the intensive care unit, blood transfusion, postoperative infection, hypoglycemic event, 
neurological dysfunction or 30-day mortality (p>0.05). 
CONCLUSIONS: In 109 patients undergoing cardiac surgery with cardiopulmonary bypass, both protocols of glycemic control 
in an intraoperative setting and in the intensive care unit were found to be safe, easily achieved and not to differentially affect 
clinical outcomes.
KEYWORDS: Cardiac surgery; Glucose control; Open-heart surgery.
INTRODUCTION 
An emerging body of medical literature has described 
the adverse consequences of hyperglycemia in a variety 
of different clinical contexts. Hyperglycemia occurs 
commonly among patients with acute neurological disease,1-5 
ischemic heart disease6-10 and a range of surgical and trauma 
events.11-13 Its development has been attributed to numerous 
stress, counter regulatory, and iatrogenic factors.14 A review15 
of 1,826 patients admitted to adult medical-surgical intensive 
care units (ICU) demonstrated a strong association between 
increasing glucose levels during ICU admission and risk of 
mortality. The lowest hospital mortality occurred among 
patients with mean glucose levels of 80 to 100 mg/dl during 52
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their ICU stay; the rate of hospital mortality increased 
dramatically for every 20 mg/dl increment above this normal 
level. 
There are relatively few studies in the literature reporting 
improved outcomes with control of blood glucose in the 
acute setting.16-19 A landmark randomized, controlled 
study18 performed in a surgical ICU included 1,548 
patients receiving mechanical ventilation, 63% of whom 
had undergone cardiac surgery. The study demonstrated 
a significant reduction in ICU mortality, reduced from 
8.0% to 4.6%, and impressive reductions in numerous 
organ system dysfunctions with an intensive regimen that 
targeted euglycemia. In addition to saving lives, intensive 
insulin therapy largely prevented several critical illness-
associated complications. The incidences of critical illness 
polyneuropathy, bloodstream infections, acute renal failure 
and anemia were reduced.18
In 2006, after the first surgical study, a second large, 
prospective, randomized controlled trial by the Leuven 
group20 was published on the effects of tight glycemic control 
in adult patients admitted to the medical ICU. In-hospital 
mortality of the intention-to-treat population of 1200 medical 
ICU patients was reduced, although not significantly. The 
lack of significance was not surprising, as the study was not 
statistically powered for this endpoint. In the target group of 
long-stay patients, maintaining normoglycemia significantly 
reduced in-hospital mortality from 52.5% to 43.0% (P=0.009). 
Morbidity was significantly reduced in the intention-to-treat 
group when they received intensive insulin therapy, where this 
reduction was even more striking in the target group. Patients 
were less dependent on prolonged mechanical ventilation 
and were discharged earlier from the ICU and hospital. In the 
subgroup of long-stay ICU patients, intensive insulin therapy 
also prevented newly acquired kidney injury, reduced the 
incidence of hyperinflammation and reduced the incidence of 
critical illness polyneuropathy or myopathy.
Questions have been raised about the efficacy of this 
technique in general and in specific subgroups. Additional 
issues include the safety of intensive insulin therapy with 
regard to the potential harm of brief hypoglycemic episodes 
and of high-dose insulin administration.21-24 In a recent study, 
the prospective, randomized, multicenter VISEP (Efficacy 
of Volume Substitution and Insulin Therapy in Severe 
Sepsis) trial was designed as a four-arm study to assess the 
choice of fluid resuscitation and the efficacy and safety of 
intensive insulin therapy in patients with severe sepsis and 
septic shock. Mortality and organ dysfunction were utilized 
as outcome parameters.25 The insulin arm of the study was 
stopped prematurely because the rate of hypoglycemia in 
the intensive treatment group was considered unacceptably 
high (12.1%). 
Data provided by recently completed trials reveal that we 
should regard tight glucose control during cardiac surgery as 
experimental and confine its use to clinical trials.23,25 In light 
of this suggestion, we aimed to investigate whether different 
targets of intraoperative and postoperative glucose (80-130 
mg/dl, 4.4-7.2 mEq/l or 160- 200 mg/dl, 8.8-11.1 mEq/l) 
could affect postoperative clinical outcomes after cardiac 
surgery with cardiopulmonary bypass. 
METHODS
Patient Selection 
The study was a prospective, randomized, controlled trial 
performed in the operating room and in the cardiac surgical 
intensive care unit (ICU). The protocol of glycemic control 
was modified from data provided in the literature18 and was 
approved by the Institution Ethics and Scientific Committee. 
Written informed consent was obtained from patients a day 
before the surgery. 
Over a period of 12 months, 300 patients were submitted 
to cardiac surgery at InCor – Heart Institute. Of these 300 
patients, 191 were excluded; 39 patients due to renal failure, 
116 patients because they required inotropic support and 
36 patients because of emergency surgery. One–hundred-
nine patients scheduled for open-heart surgery requiring 
cardiopulmonary bypass (CBP) were enrolled. The patients 
were randomized into two groups through a lottery system. 
The first group was named the “treated group” (intensive 
protocol), with a target glucose level between 80-130mg/dl. 
The second group was the “control group” (less intensive), 
with a target glucose level between 160-200 mg/dl. In the 
latter case, infusion of insulin was initiated only if blood 
glucose levels exceeded 200 mg/dl. Continuous intravenous 
regular insulin was used to control glucose levels (regular 
insulin, U100, Biobrás, Montes Claros, Brazil) when 
protocol criteria were met, using an infusion device. 
The study group included adults from both genders who 
were older than 21 years of age and who were undergoing 
open-heart cardiac surgery with CPB. The exclusion 
criteria included: (1) renal failure (creatinine>1.5 g/dl), (2) 
neurological dysfunction (diagnosis from medical records), 
(3) chronic pulmonary obstructive disease (CPOD), (4) 
current use of any type of antibiotic, (5) current use of 
inotropic support, (6) emergency and urgent surgeries and 
(7) reoperations. 
Protocol for glycemic control
At the beginning of the study, all patients were kept 
in intraoperative rooms and were started on intravenous 53
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glucose (8–12 g/hr), which was maintained for the first 
24 hours after arrival in the ICU. After 24 hours, patients 
started a standardized feeding schedule, intended to deliver 
20–30 nonprotein calories·kg-1·24 hrs-1 with a balanced 
composition (0.13–0.26 g nitrogen·kg-1·24 hrs-1 and 20–40% 
of nonprotein calories as lipids) of enteral feeding. All of the 
patients were able to receive enteral feeding after surgery. 
Parenteral nutrition was not prescribed for any patients in the 
study. Patients were randomly assigned to either intensive 
or conventional insulin treatment. Adjustment of the insulin 
dose was based on the measurements of whole blood 
glucose in undiluted arterial blood every one to four hours, 
using a glucose analyzer (ABL700, Radiometer Medical 
A/S, Copenhagen, Denmark). The dose was adjusted by 
the intensive care nurses according to a titration algorithm 
(Leuven modified), as stipulated below. These insulin doses 
were approved by a study physician not involved in the 
clinical care of the patients. The nurses were advised to 
consider the titration algorithm as a directive rather than 
strict numerical instructions.
Insulin was given exclusively by continuous intravenous 
infusion through a central venous catheter using an infusion 
device (B. Braun, Melsungen, Germany). The standard 
concentration was 100 IU of Actrapid HM (Novo Nordisk, 
Copenhagen, Denmark) in 100 mL of 0.9% NaCl. Prepared 
solutions, which were stable for up to 12 hrs when kept at 
<25°C, were not to be used beyond that time. Whole blood 
glucose levels were measured on site in undiluted arterial 
blood. Undiluted samples were obtained by removing at least 
four times the flush volume in the arterial catheter between 
the sampling point and the arterial puncture site before the 
actual sample was taken. During the intraoperative period 
and during the first 24 hours after admission to the ICU, 
measurement of blood glucose was advised every one to two 
hours until the targeted level of blood glucose was achieved. 
Thereafter, blood glucose was measured every four hours, 
unless dramatic decreases or increases in the blood glucose 
level occurred. In these cases, hourly control was performed 
after each dose adjustment.
Adequate administration of the prescribed nutrients was 
emphasized. Intravenous glucose-containing solutions were 
administered by an infusion pump to avoid fluctuation of blood 
glucose levels and frequent adjustment of the insulin dose. At 
the time of planned interruptions of feeding, the insulin dose 
was proportionately reduced to avoid hypoglycemia. Hence, in 
a patient receiving total enteral nutrition, insulin was virtually 
stopped during the twice daily, two-hour interruptions of 
tube feeding. In some patients, however, including those with 
diabetes and those requiring insulin before ICU admission, 
a low maintenance dose was needed during that time. At 
the time of patient transportation to an investigation or to 
the operating room for surgery, all intravenous and enteral 
administration of feeding was halted, and insulin infusion 
was temporarily discontinued. The blood glucose level was 
measured to ensure that it was adequate before transport. 
Whenever a patient was extubated and allowed to initiate a 
limited intake of oral foods, the intravenous or tube feeding 
was usually reduced to allow the patient’s appetite to return. 
The insulin dose was proportionately reduced and often 
temporarily discontinued.
Initiation of Insulin Infusion and Initial Stabilization of 
Blood Glucose Level
When the blood glucose level exceeded 130 mg/dl, insulin 
was started at 2 IU/hr (4 IU/hr if the first blood glucose level 
exceeded 220 mg/dl). When the next blood glucose reading 
was >150 mg/dL, the insulin dose was increased by 1–2 IU/hr. 
When the subsequent blood glucose level was 110–140 mg/dl, 
insulin was increased by 0.5 to 1 IU/hr. When blood glucose 
approached 80–110 mg/dl, insulin was adjusted by 0.1 to 0.5 
IU/hr. When the blood glucose level was 80–110 mg/dl, the 
insulin dose was unaltered.
Dose Adjustments After Initial Stabilization
Dose adjustments were always proportionate to the 
observed change in blood glucose. When blood glucose 
decreased by >50%, the dose of insulin was reduced to half, 
and the blood glucose level was checked within the next hour. 
When blood glucose was 60–80 mg/dl, insulin was reduced 
depending on the previous blood glucose level, and the 
blood glucose level was checked again within the next hour. 
When blood glucose was 40–60 mg/dl, insulin infusion was 
stopped, an adequate baseline glucose intake was ensured, 
and the blood glucose level was checked within the next hour. 
When the blood glucose was <40 mg/dl, insulin infusion was 
stopped, an adequate baseline glucose intake was ensured, 
glucose was administered via 10 g intravenous boluses, and 
the blood glucose level was checked within the next hour. 
When blood glucose started to decrease within the normal 
range in a stable patient, recovery of insulin sensitivity was 
assumed, and the insulin dose was reduced by 20%. Additional 
blood glucose controls were advised whenever changes in 
body temperature or infection occurred.
CONVENTIONAL INSULIN THERAPY
Initiation and Dose Adjustment of Insulin Infusion
As soon as the blood glucose level exceeded 200 mg/
dl, insulin infusion was initiated at an initial dose of 1 IU/54
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hr. When a control blood glucose level was >200 mg/dl, the 
insulin dose was increased by increments of 1 IU/hr. Once 
the blood glucose level was between 180 and 200 mg/dl, 
the insulin dose was maintained constant. When the blood 
glucose level decreased to <180 mg/dl, insulin infusion was 
decreased until the blood glucose level was between 180 
and 200 mg/dl. The insulin dose was further reduced and 
eventually stopped completely when blood glucose levels 
decreased further. Insulin infusion was returned when blood 
glucose exceeded 200 mg/dl.
Intraoperative and ICU Management
Surgical and anesthesia management did not differ 
from routine care. All patients were given oral midazolam 
at 0.5 mg/kg as premedication (maximum 15 mg), 
general anesthesia with propofol (dose depending on 
hemodynamics), 0.5-1 µg/kg sufentanil, 0.5 mg/kg 
atracurium and isoflurane titrated to a hemodynamic 
effect. In accordance with the routine protocol, 20 mg/
kg methyilprednisolone (maximum 1 g) was given after 
induction of anesthesia. The use of inotropic support was 
dependent on patients’ needs. The threshold for a red blood 
cell blood transfusion was a hematocrit of less than 30%. 
Second generation cephalosporin was given as prophylaxis 
before sternotomy and after cardiopulmonary bypass 
(CPB), per hospital protocol. Antifibrinolytic therapy 
with aminocaproic acid was used as needed according to 
institutional protocol. Lactated Ringer’s solution was used to 
increase the volume. Cardiopulmonary bypass temperature 
depended on the type of surgery and varied from profound 
to mild hypothermia. Hematocrit, before and after CPB, was 
set above 30% and, during CPB, between 23-25%. 
All subjects who met criteria for the study started glucose 
control after arrival in the operating room, immediately after 
standard monitoring, anesthesia induction and tracheal 
intubation. They were subsequently examined every hour 
until the end of the operation. Then, on admittance to the 
ICU, hourly glucose control resumed until glucose levels 
stabilized, and at that time, glucose control was performed 
every 2 hours for 36 hours. The glucose level was determined 
in blood samples and measured by a glucose meter (Accu 
Check Advantage, Roche, Manheim, Germany), which 
proved to be precise and exact when handled by trained 
personnel.26
Analyzed Variables 
Patients’ anthropometric and clinical characteristics were 
collected, and pre-operative cardiac and risk evaluations were 
applied. The type of surgery performed, the duration of the 
surgery and the elapsed time of CPB were also registered.
Primary outcomes were clinical outcomes, which 
included the duration of mechanical ventilation from the 
operation room until extubation in the intensive care unit 
(ICU), the length of stay in the ICU, occurrence of infection 
(diagnosis of pneumonia, urinary tract infection, sepsis, 
septic shock, wound infection, blood stream infection, 
catheter infection), occurrence of hypoglycemia (glucose 
level <50 mg/dl), renal dysfunction (characterized as an 
increase in the level of creatinine higher than 50% of the 
baseline value), neurological dysfunction (diagnosis by 
hospital neurologist who was blinded to the protocol), red 
blood cell transfusion during the first 30 days after surgery, 
the length of stay in the hospital and mortality by 30 days 
after surgery. We contacted patients by telephone and used 
a standardized telephone survey at 30 days after surgery 
to assess outcomes that occurred after discharge. The 
physicians and nurse who obtained the clinical data were 
blinded to the randomization of the group.
Statistical analysis
The student T-test was used to assess differences between 
the two groups regarding age, weight, height and corporeal 
mass index. The Fisher χ2 exact test was utilized, when 
appropriate, to compare the treated and control groups 
regarding sex, physical status, incidence of renal failure, 
presence of infection, use of antifibrinolytics, neurological 
dysfunction and mortality. The Mann-Whitney test was 
employed to assess differences concerning cardiac operative 
risk evaluations, preoperative laboratory data, duration of 
surgery, CPB time, duration of intubation, length of stay 
in the hospital and ICU, blood transfusion and amount of 
antifibrinolytic used. The ANOVA test was used to compare 
data from both groups regarding the glucose levels obtained 
during surgery and in the ICU. 
RESULTS
The results of this study are presented in tables and 
figures with mean age and standard deviation or median 
when suitable. Eleven patients from both groups were 
withdrawn from the study; five of them required a second 
operation due to bleeding, three had hemodynamic instability 
that required an aortic balloon, and three had serious 
ventricular tachycardia that required electric shock. Ninety-
eight patients were enrolled in this study, including fifty-one 
in the control group and forty-seven in the treated group. 
Thirty-two patients were diagnosed with diabetes 
mellitus and sixty-six were diagnosed as non-diabetic. Table 
1 shows the anthropometric characteristics of the patients in 55
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Table 1 - Anthropometric characteristics, preoperative risk 
and preoperative laboratory data
Control Group 
(n=55)
Treated Group 
(n=54)
Male (%) 56.9 43.1
Age (years), mean (SD)  58 (± 12) 57 (± 12)
Weight (kg), mean (SD) 68.7 (± 12.9) 63.3 (± 11.2)
Height (cm), mean (SD) 162.5 (± 8.4) 162.1 (± 8.3)
BMI, mean (SD)  26 (± 4.9) 24 (± 3.4)
ASA (physical status) – P4 (%) 86.3 70.2
EuroSCORE, mean( SD) 3.5 (± 2.1) 3.2 (± 2.2)
Canadian, mean(SD)  3.0 (± 2.4) 3.0 (± 2.3)
Parsonnet, mean(SD)  11.1 (± 6.1) 11.3 (± 7.0)
Glucose preop 138.4 (± 74.6) 113.4 (± 42.5)
Cholesterol  220.8 (± 135.7) 189.1 (± 42.3)
Triglycerides  135.5 (± 62.4) 122.7 (± 63.8)
Creatinine  76.3 (± 18.9) 72.1 (± 17.7)
Hematocrit - % 40.9 (± 3.9) 41.7 (± 4.5)
*P ≤ 0,05 value statistically significant
Obs: Glucose preop = glucose level preoperative, mg/dl; Cholesterol = 
total cholesterol, mg/dl; Triglycerides = mg/dl; Creatinine = creatinine 
clearance ml/min; P ≤ 0,05 value statistically significant
Table 2 - Diagnostic categories
Procedures Control Group 
(n=55)
Treated Group 
(n=54)
Coronary artery bypass graft 
(CABG)
19 16
Combined CABG and mitral valve 
plastic or replacement
0 2
Combined CABG and aortic v. 
replacement
4 4
Combined CABG and correction of 
ventricular aneurysm
1 5
Mitral v. plastic or replacement 7 13
Aortic v. plastic or replacement 11 6
Combined mitral v. replacement and 
tricuspid exploration
3 5
Combined mitral v. plastic and aortic 
v. replacement
4 3
Ascending aortic aneurysm cor-
rection
2 0
Atrial septal defect closure  3 0
Complex* 1 0
Obs: Complex*: combined ascending aortic aneurysm correction + aortic 
valve replacement + CABG
Table 3 - Operative data
Control Group 
(n=55)  
Treated Group 
(n=54)
P
Length of surgery (min), 
mean (SD) 
310.4 (± 111.0) 271.4 (± 66.2) 0.122
Length of CPB (min), 
mean (SD) 
116.3 (± 54) 97.9 (± 45.3) 0.060
Antifibrinolytics (%) 68.6 57.5 0.240
P ≤ 0,05 value statistically significant
both groups. The control and treated groups were comparable 
with respect to age, gender and height, but the treated group 
was slimmer and had a lower body mass index (BMI).
There were some slight differences in the treated and 
control groups related to the classification of physical status 
by the ASA (American Society of Anesthesiologists). In 
the control arm of the study, 86.3% of the patients were P4 
and, in the treated arm, 70.2% of the patients were P4. After 
applying the risk evaluation for cardiac surgical patients 
from EuroSCORE27 and from Canadian research,28 
no differences were found between the two groups. The 
same results were obtained when the risk evaluation from 
Bernstein and Parsonnet29 was applied (Table 1). Glucose 
level, total cholesterol, hematocrit and triglycerides before 
surgery were similar between the two studied groups. 
Although similar, clearance of creatinine in both groups was 
mildly lower than the normal range (Table 1). The type of 
surgical procedure is described on Table 2. 
Neither the type of surgery, duration of surgery or the CPB 
time was different between the two study groups (Tables 3). 
The use of antifibrinolytics until extubation in the ICU also 
showed no statistically significant differences between the 
two groups; the duration of use ranged from 10 hours to 15 
minutes in the control group and 10 hours to 55 minutes in the 
treated group. In relation to the length of stay in the ICU, both 
groups were comparable, with 5.9 days for the control group 
and 4.1 days for the treated group (p=0.481).
The mean glucose level during the protocol period was 
126.69 (± 10.82) mg/dl in the treated group and 168.21 (± 
28.29) in the control group. These results were statistically 
different (Figure 1).
The intensively treated patients (Table 4) received higher 
total and daily doses of insulin compared to the control 
group (p<0.05). 
Clinical outcomes were not different between the two 
groups. Primary and secondary outcomes were parallel 
(p>0.05). The duration of intubation from anesthetic 
induction was also quite similar in both groups (p=0.831). 
Both groups were comparable regarding the use of 
allogeneic blood. Four units of packed red cells were used 
in the control group in comparison with 3.5 units in the 
treated group (p=0.20), as shown in Table 5. The rate of 
hypoglycemia, which was considered to be the ratio of the 56
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Figure 1 - Glucose levels (mg/dL) in control and intensively treated groups. 
Standard deviation is represented below
Table 4 - Total and daily doses of insulin in each group
Risk Control Group 
(n=55)
Treated group 
(n=54)
P
Patients who received 
insulin, (%)
49 (100) 43 (87.7) 0.21
Daily doses of insulin, 
mean (SD)
8 (± 6) 61  (± 26) 0.04*
Total doses of insulin, 
mean (SD)
28 (± 9) 121 (± 34) 0.03*
*P ≤ 0,05 value statistically significant
Table 5 - Clinical outcomes
Control Group 
(n=55)
Treated Group 
(n=54)
P 
(CI 95%)
Duration of intubation 
(hours/min), median *
10h 15min  10h 55min 0.831 
(0.24-1.78)
ICU length (days), mean 
(SD)
5.9 (± 10.2) 4.1 (± 6.9) 0.481 
(0.44-1.67)
Hypoglicemia  (%) 2.1 2.9 0.67 
(0.84-1.43)
Blood transfusion (units), 
mean (SD)
4 (± 2.8) 3.5 (± 3.2) 0.202 
(0.65-1.34)
Infection rate (%) 35.3 19.2 0.119 
(0.23-2.2)
Postoperative fever (%) 11.1 0.0 0.123 
(0.24-1.1)
Renal dysfunction (%) 9.8 6.4 0.717 
(0.67-1.45)
Neurological dysfunc-
tion (%)
9.8 2.1 0.207 
(0.34-1.65)
Hospital length (days), 
mean (SD) 
17 (± 16) 12 (± 7) 0.060 
(0.24-1.01)
Death (%) 5.9 6.4 1.0 
(0.24-1.2)
P ≤ 0,05 value statistically significant
* mean values are very variable: 37h 11min (± 80h 7 min) in control group 
and 31h 50min (± 141h 58min) in treated group 
hypoglycemic episodes per number of glucose measurements 
(2.1% in the control group and 2.9% in the intensive group, 
p=0.67), was similar between the groups.
Although 35.3% of the patients from the control group 
and 19.2% of the patients from the treated group had a 
postoperative infection, this difference did not reach statistical 
significance (p=0.11). Table 5 describes the documented 
infections. Respiratory tract infections were the most common 
infection, and both groups had the same frequency of this type 
of infection. There were no cases of septic shock, catheter 
infection or bloodstream infection. Renal dysfunction occurred 
in 9.8% of the patients from the control group and 6.4% of 
the patients from the treated group, without any statistically 
significant difference (Table 6).
No differences between groups were found concerning 
neurological dysfunction. A neurologist blinded to 
the protocol examined all of the patients and detected 
neurological dysfunction in 9.8% of the patients in the 
control group and 2.1% in the treated group. The length of 
stay in the hospital was slightly different between the two 
groups, with the control group staying 17 days compared to 
12 days for the treated group. However, this difference was 
not statistically significant. Finally, the survival rate was 
examined as the principal end-point at postoperative day 30, 
Table 6 - Types of Infection  
Control Group 
(n=55)
Treated Group 
(n=54)
P 
(CI 95%)
Respiratory tract 
(RT)
38.9% 44.4% 0.4 
(0.45-1.31)
Infection of urinary 
system (IUS)
11.1% 22.2% 0.31 
(0.66-1.81)
Sepsis 11.1% 22.2% 0.31 
(0.64-1.76)
Surgical Wound 16.7% 11.1% 0.09 
(0.3-1.2)
P ≤ 0,05 value statistically significant57
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and the results were not different between groups (p=0.71), 
as shown in Table 7. 
DISCUSSION
The main results of our study demonstrate that there 
are no significant differences between our two groups, the 
intensively treated (glucose level of 80-130 mg/dl) and 
the control (glucose level of 160-200 mg/dl). Specifically, 
we examined the duration of mechanical ventilation, the 
length of stay in the ICU and hospital, the incidence of post-
operative infection, required units of blood for transfusions, 
incidence of renal dysfunction, presence of neurological 
dysfunction and number of deaths within 30 days after the 
operation. 
Patients from both groups were comparable with regard 
to age, gender and height, but they differed in weight and 
body mass index. In addition, there were no differences 
between the control and treated groups for physical status 
(ASA), as well as Canadian and EuroSCORE indices of 
risk. Diabetes mellitus and morbid obesity are considered 
risk factors in cardiac surgeries only in the score index 
proposed by Bernstein and Parsonnet; both groups were 
similar considering these co-morbidities.
The regular use of methylprednisolone, administered as 
a single dose after anesthetic induction, is justified by some 
studies to attenuate the inflammatory response to CPB.3,30 It 
is likely that methylprednisolone contributed to additional 
elevation of serum glucose levels in our patients. The 
examined groups did not show any differences concerning 
intraoperative variables, including duration of surgery, length 
of CPB and usage of antifibrinolytic.
The results of our study are different from those of 
other recent . These differences could be explained by the 
different populations examined and/or by the methodological 
design.18-20,22 The patients included in our series were 
scheduled for elective surgeries; therefore, emergency 
surgeries, patients with renal dysfunction and patients using 
inotropic support were excluded from this study. These same 
exclusion factors did not apply to patients in the studies by 
Van den Berghe et al. and Krinsley et al.15,18 These studies 
included surgical and clinical ICU patients, most of whom 
had post-operative complications or decompensate clinical 
diseases. Another possible reason for the lack of statistical 
significance in results from the two groups in the present 
study is the relatively limited duration of glucose control, 
since it was maintained only during surgery and for 36 hours 
in the ICU. Studies which demonstrated a benefit from strict 
control of the glucose level on outcomes included protocols 
with durations longer than 5 days.15,18,20 
Hyperglycemia is common in intensive care unit patients, 
and the severity of hyperglycemia has been repeatedly 
associated with adverse outcomes of a variety of illnesses, 
including critical illnesses. Traditionally, insulin is not 
administered until blood glucose exceeds 180–200 mg/
dl, based on the rationale that such mild increases are not 
deleterious, and tighter control might be complicated by 
life-threatening hypoglycemia. In 2001, a large, randomized, 
controlled study revealed that intensive insulin therapy to 
maintain normal blood glucose levels (<110 mg/dl) saved 
lives and prevented debilitating and expensive complications 
in a predominantly surgical ICU population.18 This study 
was followed with a publication by Krinsley et al.,19 who 
reported that when intensive insulin therapy is implemented 
in real-life intensive care situations, the benefits on morbidity 
and mortality are largely reproduced. The subsequent 
randomized, controlled study of intensive insulin therapy in 
a very ill medical ICU population, with a high co-morbidity 
and a high risk of death, confirmed the morbidity benefits 
and, when blood glucose control was continued for at least 
three days, reduced mortality.20 Hence, since the 2001 
publication, which has been strongly supported by other 
more recent studies, many centers have initiated blood 
glucose control in their ICUs. 
Recent reports question whether this protocol fits all 
patients and if consequent hypoglycemia, which is the 
risk of controlling blood glucose with insulin, could have 
a negative impact on patient outcomes.22-25 Blood glucose 
control with insulin has an associated risk of hypoglycemia. 
In both of the studies mentioned above, hypoglycemia 
occurred more frequently in patients who did not survive. 
However, as hypoglycemia was associated with mortality 
in both insulin therapy groups, it remained unclear whether 
this association was causal. Fears of hypoglycemia and its 
imagined consequences, based on deeply rooted emotional 
beliefs rather than evidence, explain why hypoglycemia is 
often considered more dangerous than hyperglycemia in the 
critically ill. Hypoglycemia is generally arbitrarily defined 
as blood glucose <50 mg/dl with neuroglycopenic symptoms 
or <40 mg/dl in the absence of symptoms. In the ICU, 
however, sedation may mask symptoms of neuroglycopenia, 
and counter-regulatory responses may be impaired, which 
complicates the diagnosis of hypoglycemia in this setting. 
Thus, the clinical relevance of a brief hypoglycemic episode, 
independent of illness severity, remains unclear.32,33 
Table 7 - Rates of survival after 30 days of surgery.
Control Group (n=55) Treated Group (n=54)  P
52 (94.5%) 52 (96.2%) 0.31
P ≤ 0,05 value statistically significant58
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In our study, hypoglycemia occurred in 2.1% of the 
control group and in 2.9% of patients from the treated group, 
with no statistical difference between groups. There were 
no cases of neurological sequelae of hypoglycemia, which 
suggests that the protocol was safe in this population.
One important point that deserves discussion is the fact 
that 11 patients were lost to follow-up, which may have 
biased the results. 
Vriesendorp et al.34 assessed the effect of incidental 
hypoglycemia on outcomes of critically ill patients. The risk 
of hypoglycemia with this regimen was 6.9%. They studied 
a total of 302 patients. Matching of cases and controls was 
performed for age, sex, severity of illness, and duration of 
ICU stay before the hypoglycemic event. They found no 
association between hypoglycemia and early (within five 
days of the event) or late (hospital) mortality. The data 
reported by Vriesendorp et al. suggest against using the risk 
of hypoglycemia as a reason to avoid intensive insulin therapy. 
The prospective, randomized, multicenter VISEP (volume 
substitution and insulin therapy in severe sepsis) trial was 
designed as a four-arm study to assess the choice of fluid 
resuscitation and the efficacy and safety of intensive insulin 
therapy in patients with severe sepsis and septic shock, using 
mortality and organ dysfunction as outcome variables.24 The 
insulin arm of this study was stopped prematurely because the 
rate of hypoglycemia in the intensive treatment group (12.1%) 
was considered unacceptably high. In our study, we had a low 
rate of hypoglycemia that was similar between groups (2.9% 
in treated group vs. 2.1% in control group, p=0.67), and these 
results can be explained in part by the acquired glucose levels 
(126.69 (± 10.82) mg/dl in the treated group and 168.21 (± 
28.29) mg/dl in the control group). Consequently, it is possible 
to assume that the use of this protocol may be safe in patients 
undergoing open-heart surgeries, although the glucose levels 
remain higher than classical recommendations, which could 
explain our results. This study, which applied less intensive 
glycemic control, had good outcomes and did not result in 
excess hypoglycemia. This data contrasts with those from 
a recent study35 which showed that strict intraoperative 
glycemic control (glucose levels between 80 and 100 mg/dl) 
is associated with higher rates of death and stroke. 
Several recent studies clearly identify the development of 
hyperglycemia as an important risk factor for mortality and 
morbidity of critically ill patients. In patients undergoing 
cardiac surgery, hyperglycemia has been associated with 
a substantial mortality risk and delayed extubation.36 
Intraoperative hyperglycemia seemed to be an independent 
risk factor for adverse outcome after cardiac surgery.37-42 
Furthermore, hyperglycemia was associated with an 
increased risk of death in patients with myocardial infarction 
and also in patients with risk of congestive heart failure 
and cardiogenic shock.38 From the predictive value of 
hyperglycemia for decreased survival of patients with a 
severe brain injury, a significant relationship was found 
between high blood glucose levels and impaired neurological 
status, weakened pupil reactivity, intracranial hypertension 
and a longer hospital stay.43,44 In addition, a strong link has 
been described between increased blood glucose levels and 
the risk of critical illness polyneuropathy in sepsis and the 
systemic inflammatory response syndrome.44 Results of 
multiple-center trials on tight blood glucose control in the 
critically ill and of studies on the most optimal level of blood 
glucose for different patient populations are still lacking. 
While we await those results, the current evidence, largely 
provided by the two Leuven trials and the implementation 
study by Krinsley, is in favor of controlling blood glucose 
levels in the ICU. Indeed, these studies showed that 
many lives were saved with this intervention, despite a 
higher prevalence of hypoglycemia. Hyperglycemia is 
deleterious for critically ill patients. Dr. Vriesendorp and 
colleagues34 have now shown that incidental, brief episodes 
of hypoglycemia, when rapidly recognized and appropriately 
treated, are not likely to cause serious harm. 
To safely target normoglycemia in ICU patients, 
intensivists and ICU nurses alike anxiously await accurate, 
continuous blood glucose sensors. This vital tool should 
be added to the bedside monitor, with appropriate alarms 
and trends to facilitate safe implementation of insulin 
therapy. Ideally, a closed-loop computerized system with 
an accurate continuous sensor and an insulin pump linked 
via an automated algorithm will conserve precious nursing 
time.44 Such devices are not yet available, and systems that 
are commercially available and perform relatively well for 
patients with diabetes do not work for critically ill patients. 
It is hoped that validated systems will become available 
soon and find their way to the ICU. In this study, we used a 
glucose meter that is widely available in ICUs world-wide.
Although this pilot study showed no difference in clinical 
outcomes among the two study groups, the sample size was 
not large enough to allow for any definite conclusions or 
recommendations on the effect of strict glucose control versus 
less intensive control. However, the sample size is sufficient 
to address the following important questions. Who are the 
patients that really benefit from strict glucose control? What 
is the safest protocol regarding hypoglycemic events? Do the 
patients improve with glucose control or solely because of the 
improved care included in the protocols? Our study showed 
that in a population of 109 patients undergoing cardiac surgery 
with cardiopulmonary bypass, both protocols are safe, can be 
easily achieved and do not differ regarding clinical outcomes. 
However, due to the small study sample, a clinically relevant 
effect in the population could not be excluded. 59
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